Tier B · Substantial human research
Retatrutide
The most closely watched next-generation metabolic peptide program.
Why researchers care
Potential human relevance
- Phase 2 trials showed very large average body-weight reductions
- Designed to combine appetite, insulin and energy-expenditure signaling
- Phase 3 programs are studying obesity and several obesity-related conditions
What the human evidence says
Evidence, not extrapolation
Retatrutide has strong phase 2 human data and multiple active phase 3 programs. As of July 2026 it remains investigational and is not an FDA-approved drug.
How to think about it
The Yooper Peptides take
Its significance is mechanistic: one molecule activates three metabolic hormone receptors. That makes it a test of how far multi-agonist peptide engineering can go.
Primary / authoritative reading